Inhibition of alloresponsive naive and memory T cells by CD7 and CD25 antibodies and by cyclosporine.
Human naive and memory T cells can be isolated from each other by their CD45RA and CD45RO expression, respectively. This enables the assessment of their differential sensitivities to immunosuppressive agents for the first time. We have investigated the ability of cyclosporine or CD7 and CD25 antibodies to selectively block alloantigen stimulated naive and memory T cells in vitro. CD7 antibodies blocked the proliferation of naive (P less than 0.025) but not memory T cells in a primary MLR. CD25 antibody inhibited both naive and memory subsets but a significantly greater effect was found on the memory T cells (P less than 0.005). The constitutive CD7 and CD25 antigen expression on resting naive or memory T cells was related to the inhibitory activities of these antibodies on both subsets. Accordingly, naive T cells expressed more CD7 antigen than memory cells while memory T cells displayed low levels of CD25 antigen that was absent from naive populations before activation. Cyclosporine, like CD25 antibody, inhibited both subsets in a primary MLR but had a greater effect on memory cells (P less than 0.02). Memory T cells, therefore, are more dependent than naive cells on IL-2 for proliferation. There was great individual variation in the ability of CsA to block the MLR. The simultaneous addition of CD25 or CD7 antibody together with CsA, however, enhanced the MLR inhibition as the effects of all three were additive. This suggested interference by these agents at different points during T cell activation. Thus, in CsA sensitive individuals, one-tenth of the optimal CsA concentration together with CD25 antibody maintained maximum immunosuppression in vitro. These results demonstrate the possibility of using CD7 and CD25 antibodies for selective inhibition of naive or memory T cells and also the possibility of augmenting the inhibition of and reducing the CsA concentration required for clinically effective immunosuppression.
Akbar
A N
AN
Department of Immunology, Royal Free Hospital School of Medicine, London, England.
Amlot
P L
PL
Ivory
K
K
Timms
A
A
Janossy
G
G
D000911:Antibodies, Monoclonal / Q000276:immunology; D015703:Antigens, CD / Q000502:physiology; D019011:Antigens, CD7; D000943:Antigens, Differentiation / Q000502:physiology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000502:physiology*; D003524:Cyclosporins / Q000494:pharmacology*; D006649:Histocompatibility Antigens / Q000502:physiology; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects*; D007165:Immunosuppression Therapy; D007519:Isoantigens / Q000276:immunology; D017493:Leukocyte Common Antigens; D007959:Lymphocyte Culture Test, Mixed; D015375:Receptors, Interleukin-2 / Q000502:physiology*; D016176:T-Lymphocyte Subsets / Q000187:drug effects*; D013601:T-Lymphocytes / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D019011:Antigens, CD7; D000943:Antigens, Differentiation; D000945:Antigens, Differentiation, T-Lymphocyte; D003524:Cyclosporins; D006649:Histocompatibility Antigens; D007519:Isoantigens; D015375:Receptors, Interleukin-2; D017493:Leukocyte Common Antigens